The Albert Einstein Cancer Center in the Bronx serves a catchment area with large Hispanic and African American minority population. We have conducted several large cohort studies in the Bronx population that demonstrated that prevalence, disease severity and prognosis differ in minority populations for leukemias, myelodysplastic syndromes and anemias(1-6). These studies were conducted by analysis of large cohorts of outcome data stored in the clinical looking glass software developed by Montefiore Medical Center. Furthermore, we have demonstrated that we can conduct large scale cancer specific biomarker on primary patient samples. We recently built a biorepository of samples from 3000+ firefighters who were exposed to the 911 WTC disaster and studied the rates of MGUS and myeloma with proteomic analysis. Using this cohort, we have conducted preliminary studies in 781 individuals that show a significantly increased rate of monoclonal gammopathy (MGUS), a precursor for multiple myeloma in first responder firefighters (Landgren et al, JAMA Oncology, 2018) (7). Furthermore, we have demonstrated capabilities in separating malignant plasma cells from primary myeloma samples (N=50) and using them for epigenomic analysis demonstrating large scale changes in DNA methylation in myeloma (Heuck et al, J Immunol) (8). Having demonstrated our capabilities in conducting epidemiological and biomarker studies, we now propose to comprehensively determine the prevalence, disease characteristics and prognosis of myeloma and precursor lesion (MGUS) in large cohort of minority rich subjects in the Bronx catchment area and create a minority rich database and biorepository for the community.
Aim 1 will determine the prevalence and prognosis of myeloma and precursor MGUS in African American and Hispanic patients and create a comprehensive database using patient cohorts from the last 20 years. We will obtain outcomes from patients consisting of equal numbers of African American, Hispanic and Caucasian subjects. Disease status, Response to treatments and overall survival will be determined in an ethnic specific manner and shared with other investigators.
Aim 2 will build a biorepository of well annotated and genotyped myeloma and MGUS samples from African American and Hispanic subjects: 150 samples from patients with MGUS(N=75) and myeloma (N=75) that will be collected from equal numbers of Hispanic, African American and Caucasian subjects (approximately one third for each group). Serum samples will be used for high resolution proteomic analysis to identify the immunoglobulin subtype. Deep targeted mutational analysis will be conducted. Marrow aspirates will be used for separation of plasma cells (CD138+) that will be used for DNA and RNA for future sequencing and transcriptomic studies. These studies will build a biobank of highly clinically annotated and genotyped samples that will be used for high resolution analysis of genomic differences between myeloma/MGUS between different minority subgroups
Myeloma and its precursor lesion MGUS are found to occur increased incidence in African American subjects. The rates of incidence and overall disease outcomes of these diseases are not very well studied in Hispanics. The proposed studies will assess the epidemiological and molecular characteristics of myeloma and precursor MGUS in African American and Hispanic populations and compare them to Caucasians. We will build a comprehensive large database of myeloma outcomes and also construct a repository of samples from minorities with myeloma and MGUS. The availability of NCORP grant resources as well as a predominant minority population and excellent electronic medical record databases will enable us to successfully complete the proposed studies.
|Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903|
|Marcelletti, John F; Sikic, Branimir I; Cripe, Larry D et al. (2018) Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry B Clin Cytom :|
|Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629|
|Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121|
|In, Haejin; Langdon-Embry, Marisa; Gordon, Lauren et al. (2018) Can a gastric cancer risk survey identify high-risk patients for endoscopic screening? A pilot study. J Surg Res 227:246-256|
|Rakovitch, E; Gray, R; Baehner, F L et al. (2018) Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 169:359-369|
|Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095|
|Sparano, Joseph A (2018) Prognostic gene expression assays in breast cancer: are two better than one? NPJ Breast Cancer 4:11|
|Rapkin, Bruce D; Weiss, Elisa; Lounsbury, David et al. (2017) Reducing Disparities in Cancer Screening and Prevention through Community-Based Participatory Research Partnerships with Local Libraries: A Comprehensive Dynamic Trial. Am J Community Psychol 60:145-159|
|Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519|
Showing the most recent 10 out of 35 publications